Skip to main content

Mobocertinib Dosage

Medically reviewed by Drugs.com. Last updated on Mar 12, 2025.

Applies to the following strengths: 40 mg

Usual Adult Dose for Non-Small Cell Lung Cancer

160 mg orally once a day
Duration of therapy: Until disease progression or unacceptable toxicity

Use: For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (as detected by a US FDA-approved test) whose disease has progressed on or after platinum-based chemotherapy

Renal Dose Adjustments

Mild to moderate renal dysfunction (estimated GFR 30 to 89 mL/min/1.73 m2): No adjustment recommended.
Severe renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2): Data not available

Comments:

Liver Dose Adjustments

Mild or moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction: Data not available

Comments:

Dose Adjustments

Dose reduction levels for adverse reactions:


QTc Interval Prolongation and Torsades de Pointes:

Interstitial Lung Disease (ILD)/Pneumonitis:

Decreased Ejection Fraction or Heart Failure:

Diarrhea:

Increased Amylase or Lipase:

Other Adverse Reactions:

Graded per National Cancer Institute Common Terminology Criteria for Adverse Events

Coadministration with Moderate CYP450 3A Inhibitors: Concomitant use should be avoided.

Precautions

US BOXED WARNING:


CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

General:

Monitoring:

Patient advice:

Frequently asked questions

More about mobocertinib

Patient resources

Other brands

Exkivity

Professional resources

Other brands

Exkivity

Related treatment guides

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.